Spero Therapeutics Inc (SPRO) - News Archive

Exploring Spero Therapeutics Recent Advancements and ChallengesSpero Therapeutics has been making waves in the pharmaceutical sector with its innovative drug candidates aimed at addressing serious bacterial infections a...

Spero Therapeutics Announces Significant Progress in Antibacterial Treatment with SPR720: Phase 1 Data Published in Antimicrobial Agents and ChemotherapySpero Therapeutics, a clinical-stage biopharmaceutical company foc...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)In a recent press release, Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that the Compensation Committee of the company s Board of Di...

Spero Therapeutics, Inc. recently announced the approval of 116,667 restricted stock unit awards to a new employee as an inducement under the 2019 Inducement Equity Incentive Plan. This grant was made in accordance with...

CAMBRIDGE, Mass., May 01, 2024 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a pioneering biopharmaceutical company specializing in the development of groundbreaking treatments for rare diseases and multi-drug resistant (M...

In a significant development, Spero Therapeutics, a renowned clinical-stage biopharmaceutical company, has announced that its investigational new drug (IND) application for SPR206 has received clearance from the U.S. Fo...

In recent years, the rise of antibiotic-resistant bacteria has posed a significant challenge in the treatment of complicated urinary tract infections (cUTIs). To address this issue, Spero Therapeutics, a leading biophar...